Compare Stocks: EXEL, NTRA, ARGX, and RVMD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$825.61 +0.8%	$956.23	$661.85 ▼ $1,072.75	$51.92B	0.44	347,295 shs	393,099 shs
EXEL Exelixis	$62.68 +0.7%	$56.89	$33.76 ▼ $63.39	$15.53B	0.47	2.61 million shs	1.93 million shs
NTRA Natera	$399.42 +1.5%	$358.21	$181.00 ▼ $437.41	$57.57B	1.5	1.40 million shs	1.33 million shs
RVMD Revolution Medicines	$182.15 +2.4%	$203.22	$52.48 ▼ $224.31	$39.04B	1.4	2.85 million shs	1.98 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	0.00%	-0.71%	-17.29%	-3.20%	-2.91%
EXEL Exelixis	0.00%	+3.96%	+6.63%	+12.07%	+58.55%
NTRA Natera	0.00%	-1.81%	+6.51%	+49.81%	+116.54%
RVMD Revolution Medicines	0.00%	-6.22%	-6.80%	-1.35%	+228.95%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$825.61 +0.8%	$956.23	$661.85 ▼ $1,072.75	$51.92B	0.44	347,295 shs	393,099 shs
EXEL Exelixis	$62.68 +0.7%	$56.89	$33.76 ▼ $63.39	$15.53B	0.47	2.61 million shs	1.93 million shs
NTRA Natera	$399.42 +1.5%	$358.21	$181.00 ▼ $437.41	$57.57B	1.5	1.40 million shs	1.33 million shs
RVMD Revolution Medicines	$182.15 +2.4%	$203.22	$52.48 ▼ $224.31	$39.04B	1.4	2.85 million shs	1.98 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	0.00%	-0.71%	-17.29%	-3.20%	-2.91%
EXEL Exelixis	0.00%	+3.96%	+6.63%	+12.07%	+58.55%
NTRA Natera	0.00%	-1.81%	+6.51%	+49.81%	+116.54%
RVMD Revolution Medicines	0.00%	-6.22%	-6.80%	-1.35%	+228.95%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenex	2.83	Moderate Buy	$1,151.95	39.53% Upside
EXEL Exelixis	2.35	Hold	$51.50	-17.84% Downside
NTRA Natera	2.83	Moderate Buy	$374.64	-6.20% Downside
RVMD Revolution Medicines	2.92	Moderate Buy	$242.60	33.19% Upside

Current Analyst Ratings Breakdown

Latest EXEL, NTRA, ARGX, and RVMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/19/2026	EXEL Exelixis	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
10/19/2026	EXEL Exelixis	Citizens Jmp Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Market Outperform	$55.00 ➝ $65.00
10/19/2026	NTRA Natera	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$375.00 ➝ $500.00
10/19/2026	RVMD Revolution Medicines	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$240.00 ➝ $241.00
10/16/2026	RVMD Revolution Medicines	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Market Perform ➝ Outperform
10/15/2026	NTRA Natera	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	RVMD Revolution Medicines	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	RVMD Revolution Medicines	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$275.00
10/14/2026	ARGX argenex	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$1,355.00 ➝ $1,356.00
10/14/2026	NTRA Natera	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$360.00 ➝ $460.00
10/14/2026	RVMD Revolution Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$259.00 ➝ $260.00

(Data available from 10/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenex	$4.25B	12.22	$21.50 per share	38.40	$118.34 per share	6.98
EXEL Exelixis	$2.32B	6.69	$3.05 per share	20.56	$8.06 per share	7.78
NTRA Natera	$2.71B	21.27	N/A	N/A	$12.38 per share	32.26
RVMD Revolution Medicines	$11.58M	3,371.51	N/A	N/A	$8.44 per share	21.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenex	$1.29B	$26.04	31.71	21.97	0.75	32.19%	43.59%	36.66%	N/A
EXEL Exelixis	$782.57M	$3.18	19.71	16.89	1.75	35.33%	42.17%	31.76%	10/29/2026 (Estimated)
NTRA Natera	-$208.16M	-$1.36	N/A	N/A	N/A	-7.11%	-11.38%	-7.87%	11/5/2026 (Estimated)
RVMD Revolution Medicines	-$1.13B	-$8.82	N/A	N/A	N/A	N/A	-88.20%	-57.85%	11/4/2026 (Estimated)

Latest EXEL, NTRA, ARGX, and RVMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	NTRA Natera	-$0.2697	N/A	N/A	N/A	$707.67 million	N/A
11/4/2026	Q3 2026	RVMD Revolution Medicines	-$2.34	N/A	N/A	N/A	$23.74 million	N/A
10/29/2026	Q3 2026	EXEL Exelixis	$0.8790	N/A	N/A	N/A	$646.95 million	N/A
8/6/2026	Q2 2026	NTRA Natera	-$0.4939	-$0.47	+$0.0239	-$0.47	$661.24 million	$752.75 million
8/5/2026	Q2 2026	EXEL Exelixis	$0.8530	$0.91	+$0.0570	$0.8438	$636.40 million	$628.69 million
8/5/2026	Q2 2026	RVMD Revolution Medicines	-$2.04	-$3.06	-$1.02	-$3.06	$1.77 million	N/A
7/21/2026	Q2 2026	ARGX argenex	$5.86	$7.32	+$1.46	$7.32	$1.45 billion	$1.54 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenex	N/A	N/A	N/A	N/A	N/A
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A
NTRA Natera	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenex	N/A	5.12	4.89
EXEL Exelixis	N/A	3.46	3.38
NTRA Natera	N/A	3.00	2.85
RVMD Revolution Medicines	0.40	11.38	11.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenex	60.32%
EXEL Exelixis	85.27%
NTRA Natera	99.90%
RVMD Revolution Medicines	94.34%

Insider Ownership

Company	Insider Ownership
ARGX argenex	2.43%
EXEL Exelixis	2.60%
NTRA Natera	5.05%
RVMD Revolution Medicines	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenex	1,863	62.89 million	61.36 million	Optionable
EXEL Exelixis	1,077	247.78 million	241.34 million	Optionable
NTRA Natera	6,140	144.14 million	136.87 million	Optionable
RVMD Revolution Medicines	883	214.34 million	198.05 million	Optionable

EXEL, NTRA, ARGX, and RVMD Headlines

Recent News About These Companies

Truist Financial Issues Positive Forecast for Revolution Medicines (NASDAQ:RVMD) Stock Price

October 19 at 9:41 AM | marketbeat.com

7,403 Shares in Revolution Medicines, Inc. $RVMD Purchased by SteelPeak Wealth LLC

October 19 at 4:23 AM | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Stock Rating Reaffirmed as Buy by Needham & Company LLC

October 17 at 3:34 AM | americanbankingnews.com

RVMD Moves Key Pancreatic Cancer Combo Into Phase 3, Raising RAS Market Stakes

October 16 at 12:30 PM | tipranks.com

Lilly, Pfizer, J&J among winners of EU drug recommendations this month

October 16 at 9:22 AM | msn.com

Revolution Medicines, Inc. $RVMD Stock Acquired by Assenagon Asset Management S.A.

October 16 at 3:04 AM | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Shares Up 3.4% After Analyst Upgrade

October 16 at 1:52 AM | americanbankingnews.com

Revolution Medicines' Pancreatic Cancer Drug Gets EU Panel Recommendation

October 15, 2026 | finance.yahoo.com

Revolution Medicines’ RASONQUE™ (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer

October 15, 2026 | finance.yahoo.com

Revolution Medicines' RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer

October 15, 2026 | globenewswire.com

Needham & Company LLC Reaffirms Buy Rating for Revolution Medicines (NASDAQ:RVMD)

October 15, 2026 | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Shares Climb 3.4% Following Analyst Upgrade

October 14, 2026 | marketbeat.com

Royal Bank Of Canada Forecasts Strong Price Appreciation for Revolution Medicines (NASDAQ:RVMD) Stock

October 14, 2026 | marketbeat.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Stock Has Average Target Price of $234.76 According to Brokerages

October 14, 2026 | americanbankingnews.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Stock Has Average Target Price of $234.76 According to Analysts

October 14, 2026 | marketbeat.com

Rasonque subgroup data put KRAS response differences in focus

October 12, 2026 | thepharmaletter.comT

Financial Analysis: Evogene (NASDAQ:EVGN) versus Revolution Medicines (NASDAQ:RVMD)

October 12, 2026 | americanbankingnews.com

Guggenheim Sticks to Its Buy Rating for Revolution Medicines (RVMD)

October 11, 2026 | theglobeandmail.com

Revolution Medicines (NASDAQ:RVMD) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

October 10, 2026 | americanbankingnews.com

RBC Raises Price Target on Revolution Medicines to $259 From $251, Keeps Outperform Rating

October 8, 2026 | finance.yahoo.com

Revolution Medicines (NASDAQ:RVMD) Price Target Raised to $259.00

October 8, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

EXEL, NTRA, ARGX, and RVMD Company Descriptions

argenex NASDAQ:ARGX

$825.61 +6.47 (+0.79%)

Closing price 04:00 PM Eastern

Extended Trading

$825.71 +0.10 (+0.01%)

As of 05:12 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Exelixis NASDAQ:EXEL

$62.68 +0.45 (+0.72%)

Closing price 04:00 PM Eastern

Extended Trading

$63.26 +0.58 (+0.92%)

As of 05:09 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Natera NASDAQ:NTRA

$399.42 +5.98 (+1.52%)

Closing price 04:00 PM Eastern

Extended Trading

$398.20 -1.22 (-0.31%)

As of 05:45 PM Eastern

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Revolution Medicines NASDAQ:RVMD

$182.15 +4.19 (+2.35%)

Closing price 04:00 PM Eastern

Extended Trading

$181.36 -0.80 (-0.44%)

As of 05:48 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EXEL, NTRA, ARGX, and RVMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EXEL, NTRA, ARGX, and RVMD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EXEL, NTRA, ARGX, and RVMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EXEL, NTRA, ARGX, and RVMD Company Descriptions

argenex NASDAQ:ARGX

Exelixis NASDAQ:EXEL

Natera NASDAQ:NTRA

Revolution Medicines NASDAQ:RVMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EXEL, NTRA, ARGX, and RVMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EXEL, NTRA, ARGX, and RVMD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EXEL, NTRA, ARGX, and RVMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EXEL, NTRA, ARGX, and RVMD Company Descriptions

argenex NASDAQ:ARGX

Exelixis NASDAQ:EXEL

Natera NASDAQ:NTRA

Revolution Medicines NASDAQ:RVMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools